Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Inclusion Criteria:

- Subject is healthy, as determined by medical history.

- Subject is between the ages of 15 and 23 years (not yet 24 years).

- For subjects who participated in Study MTA02, subject previously received one dose of
Menactra® vaccine or Menomune®-A/C/Y/W-135 vaccine.

- Did not participate in Study MTA19 (a subset of subjects from Study MTA02 who had
been recruited for a follow-up challenge study)

- Subject or parent/legal guardian has signed an Institutional Review Board
(IRB)-approved informed consent form and subject has signed an IRB-approved assent
form.

- Before recruitment for the second part of the study, subjects should be thoroughly
screened to ensure that they are able to comply with protocol specifications

- A negative urine pregnancy test is required for menstruating female subjects.

Exclusion Criteria:

- History of documented invasive meningococcal disease.

- Received any other meningococcal vaccine

- Received any vaccine (other than desensitization therapy for allergies) in the 28-day
period prior to enrollment

- Scheduled to receive any vaccination in the 28-day period after enrollment

- Received systemic antibiotic therapy within the 72 hours prior to collection of a
blood sample

- Actively enrolled or scheduled to be enrolled in another clinical study

- Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic,
gastrointestinal, hematologic, psychiatric, or other organ system)

- Known or suspected impairment of immunologic function

- Acute medical illness with or without fever within 72 hours or an oral temperature ≥
100.4°F (≥ 38.0°C) at the time of inclusion

- Administration of immune globulin, other blood products, or corticosteroid within 3
months of the study vaccine. Individuals on a tapering dose schedule of oral steroids
lasting < 7 days may be included in the trial as long as they have not received more
than one course within the last two weeks prior to enrollment.

- Personal or family history of Guillain-Barre Syndrome

- Suspected or known hypersensitivity to any of the vaccine components

- Unavailable for the entire study period or unable to attend the scheduled visits or
to comply with the study procedures

- Any condition, which in the opinion of the investigator would pose a health risk to
the participant.